Beijing Scitop Bio-tech Co., Ltd. Class ASZSE: 300858

Beijing Scitop Bio-tech Co: Q3 2025 saw strong revenue and profit growth, with major R&D and capacity investments

· Issued by Beijing Scitop Bio-tech Co., Ltd. Class A

Q3 2025 revenue grew 28.98% year-over-year, with net profit up 26.56%. Operating cash flow declined, but significant investments were made in R&D and production capacity. The company adjusted its restricted stock incentive plan price in August 2025.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Earlier from Beijing Scitop Bio-tech Co., Ltd. Class A

All Beijing Scitop Bio-tech Co., Ltd. Class A news releases